Introducing Signatera, a personalized, tumor-informed test
Signatera is a new blood test that can identify molecular residual disease, or recurrent cancer, sooner than existing methods, by detecting the presence of ctDNA.
Watch Video
Signatera Clinician Resources
-
-
Signatera™ for early detection of molecular residual disease using ctDNA
Detect residual disease and recurrence early in colorectal cancer (CRC). How often should Signatera be ordered for CRC patients?
Read More
-
Signatera and Altera Insurance Coverage and Billing
The first personalized ctDNA test to identify molecular residual disease and optimize treatment decisions. Read our billing guide for information about understanding Natera's genetic testing bill.
Read More
